approves stem cell therapy
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Twitter ~ Facebook
Home / Technology News / 2010 / August 2010 / August 1, 2010
US approves stem-cell therapy for humans
RSS / Print / Comments

Sydney Morning Herald

'Ponting can't be sacked as captain unless dropped from team'

Milla Jovovich on her career and family life

Hong Kong airline to replace 'fixed-back shell' economy seats after complaints

More on Sydney Morning Herald

Technology News

Now, laser technology that destroys tumours using heat
Scientists have developed a technique that heats up and destroys kidney and liver tumours. ANI

Cheap, solar-powered lamp 'most important object of the 21st century'
A cheap solar-powered lamp has joined the list of the most priceless treasures in the British Museum. ANI

Worms provide clues to declining fertility with age in women
A new study from Princeton University has revealed why fertility declines at a rate that far exceeds the onset of other aging signs in women. ANI

US approves stem-cell therapy for humans

The US Food and Drug Administration (FDA) has given a green signal to a clinical trial of embryonic stem cells as a treatment for spinal-cord injury.


Sydney, Aug 1 : The US Food and Drug Administration (FDA) has given a green signal to a clinical trial of embryonic stem cells as a treatment for spinal-cord injury.

This is the first time embryonic stem cells will be tested on humans.

Geron Corporation, which developed the treatment, said the FDA had removed a clinical hold on its GRNOPC1 therapy.

It hopes to start testing GRNOPC1 on humans by the end of this year, enrolling eight to 10 patients across the US.

The trial will last about two years, with each patient being studied for one year.

The FDA accepted Geron's January 2009 study application, but then placed any potential study on hold last August because some mice treated with GRNOPC1 developed spinal cysts, reports The Sydney Morning Herald.

However, Geron claims to have found a new way to test GRNOPC1 and said it did not see any cysts in a separate animal study.

A successful test would lead to larger and longer studies that would focus on the effectiveness of GRNOPC1.

The company says it will monitor patients for 15 years for safety.

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us